ProCE Banner Activity

ASCENT: Phase II Study of Fixed-Duration Therapy With Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone for High-Risk Smoldering MM

Slideset Download
Conference Coverage

Combination daratumumab/carfilzomib/lenalidomide/dexamethasone given for a fixed duration of 2 years was well tolerated and is associated with a high response rate in patients with high-risk smoldering multiple myeloma.

Released: December 13, 2022

Expiration: December 12, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen